Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Characterizing systemic exposure of inhaled drugs: application to the long-acting β2-agonist PF-00610355.

Diderichsen PM, Cox E, Martin SW, Cleton A, Ribbing J.

Clin Pharmacokinet. 2013 Jun;52(6):443-52. doi: 10.1007/s40262-013-0048-7.

PMID:
23494982
2.

Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease.

Diderichsen PM, Cox E, Martin SW, Cleton A, Ribbing J.

Br J Clin Pharmacol. 2013 Nov;76(5):752-62. doi: 10.1111/bcp.12080.

3.

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA).

Bjermer L, Kuna P, Jorup C, Bengtsson T, Rosenborg J.

Drug Des Devel Ther. 2015 Feb 5;9:753-62. doi: 10.2147/DDDT.S66049.

4.

Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.

Bjermer L, Rosenborg J, Bengtsson T, Lötvall J.

Ther Adv Respir Dis. 2013 Oct;7(5):264-71. doi: 10.1177/1753465813497527.

PMID:
23907810
5.
6.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005.

PMID:
22789766
7.

Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease.

Nielsen JC, Hutmacher MM, Cleton A, Martin SW, Ribbing J.

J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):619-34. doi: 10.1007/s10928-012-9274-0.

PMID:
23001588
9.

Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.

Borghardt JM, Weber B, Staab A, Kunz C, Formella S, Kloft C.

Br J Clin Pharmacol. 2016 Mar;81(3):538-52. doi: 10.1111/bcp.12780.

PMID:
26348533
10.

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.

Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.

Respir Res. 2015 Feb 15;16:25. doi: 10.1186/s12931-015-0184-8. Review.

11.

Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.

Goyal N, Beerahee M, Kalberg C, Church A, Kilbride S, Mehta R.

Clin Pharmacokinet. 2014 Jul;53(7):637-48. doi: 10.1007/s40262-014-0143-4.

PMID:
24756395
12.

A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.

Sovani MP, Whale CI, Tattersfield AE.

Drug Saf. 2004;27(10):689-715. Review.

PMID:
15350154
13.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
14.

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.

Ribeiro M, Chapman KR.

Int J Chron Obstruct Pulmon Dis. 2012;7:145-52. doi: 10.2147/COPD.S19805. Review.

15.

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.

Ni Chroinin M, Greenstone IR, Danish A, Magdolinos H, Masse V, Zhang X, Ducharme FM.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD005535. Review. Update in: Cochrane Database Syst Rev. 2010;(5):CD005535.

PMID:
16235410
16.

Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.

Daley-Yates PT, Mehta R, Chan RH, Despa SX, Louey MD.

J Aerosol Med Pulm Drug Deliv. 2014 Aug;27(4):279-89. doi: 10.1089/jamp.2013.1040.

PMID:
24074143
17.

Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Spencer S, Karner C, Cates CJ, Evans DJ.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD007033. doi: 10.1002/14651858.CD007033.pub3. Review.

PMID:
22161409
18.

The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.

Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, Lettis S, Barnhart F, Haumann B.

Chest. 2012 Jul;142(1):119-27. doi: 10.1378/chest.11-2231.

PMID:
22241764
19.

Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Spencer S, Evans DJ, Karner C, Cates CJ.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007033. doi: 10.1002/14651858.CD007033.pub2. Review. Update in: Cochrane Database Syst Rev. 2011;(12):CD007033.

PMID:
21975759
20.
Items per page

Supplemental Content

Support Center